PDIA6 promotes glioma malignancy by activating the IRE1α- p-HSP27 signaling axis

Technical Summary: PDIA6 Promotes Glioma Malignancy by Activating the IRE1α-p-HSP27 Signaling Axis

Problem Statement
Glioma remains the most aggressive primary brain tumor in adults, characterized by rapid proliferation, invasive growth, and poor prognosis. While Protein Disulfide Isomerase A6 (PDIA6) is known to be overexpressed in various cancers (e.g., pancreatic, gastric, and renal cell carcinomas) and functions as a chaperone in protein folding and stress responses, its specific role in glioma progression has been inadequately understood and inconsistently reported in previous literature. Furthermore, the precise molecular mechanisms linking PDIA6 to the Unfolded Protein Response (UPR) and downstream malignant phenotypes in glioma remain undefined. This study addresses the gap in understanding how PDIA6 influences glioma malignancy and whether it acts through the UPR signaling pathway, specifically the IRE1α branch, to regulate Heat Shock Protein 27 (HSP27).

Methodology
The study employed a multi-faceted approach combining clinical bioinformatics, molecular biology, in vitro functional assays, and in vivo xenograft models:

• Clinical and Bioinformatic Analysis: PDIA6 expression was assessed in 142 clinical glioma samples and 35 non-neoplastic brain tissues using qPCR, Western blot, and Immunohistochemistry (IHC). Correlations with pathological grade and patient prognosis were analyzed using public databases (GEPIA, TIMER2.0, R2 platform, and TCGA).
• Cellular Models: Human glioma cell lines (U87MG, T98G, A172, LN229) and normal astrocytes were utilized. Stable cell lines with PDIA6 knockdown (sh-PDIA6) and control groups were generated via lentiviral transfection.
• In Vitro Functional Assays: Cell proliferation was measured using CCK-8 assays. Migration and invasion capabilities were evaluated via Scratch (wound healing) and Transwell invasion assays, respectively.
• In Vivo Xenograft Models: Intracranial xenografts were established in 4-week-old female BALB/c nude mice using LN229 cells. Tumor growth and volume were monitored using 7.0T Magnetic Resonance Imaging (MRI) at day 28. Survival rates and tumor histology (H&E and Ki-67 IHC) were analyzed.
• Mechanistic Investigation:
  • UPR Pathway Analysis: Protein levels of UPR sensors (IRE1α, PERK, ATF6) were quantified via Western blot following PDIA6 modulation.
  • Phospho-Kinase Screening: A human phospho-kinase array was used to identify downstream signaling changes in PDIA6-knockdown cells.
  • Rescue Experiments: To validate the signaling axis, researchers performed IRE1α overexpression in PDIA6-knockdown cells and p-HSP27 (S78) overexpression in PDIA6-knockdown cells to observe the restoration of malignant phenotypes.

Key Results

1. PDIA6 Upregulation and Prognostic Value: PDIA6 was significantly upregulated in glioma tissues compared to normal brain tissue at both mRNA and protein levels. Its expression positively correlated with higher WHO pathological grades (Grade 2 to Grade 4). High PDIA6 expression was consistently associated with shorter overall survival across multiple independent cohorts (GEPIA, French Glioma, and TCGA datasets).
2. Functional Impact of PDIA6 Knockdown: Silencing PDIA6 in LN229 and T98G cells significantly suppressed cell proliferation, migration, and invasion in vitro. In vivo, PDIA6 depletion led to a marked reduction in tumor volume, sharper tumor borders with reduced invasion into adjacent brain tissue, decreased Ki-67 positivity, and prolonged survival in mice.
3. Mechanism via UPR and IRE1α: PDIA6 knockdown specifically reduced the protein levels of IRE1α, while PERK and ATF6 levels remained unchanged. Restoring IRE1α expression in PDIA6-deficient cells rescued the suppressed proliferative, migratory, and invasive capabilities, confirming IRE1α as a critical downstream effector.
4. Downstream Signaling via p-HSP27: Phospho-kinase array screening identified a significant reduction in the phosphorylation of HSP27 at Ser78 and Ser82 (p-HSP27) upon PDIA6 knockdown, while total HSP27 levels remained stable. Western blot confirmed that PDIA6 depletion decreased p-HSP27 (S78). Crucially, overexpression of p-HSP27 (S78) in PDIA6-knockdown cells reversed the inhibition of proliferation, migration, and invasion, without altering PDIA6 or IRE1α expression levels.

Significance and Claims
The authors conclude that PDIA6 acts as an oncogene in glioma, driving malignancy through the activation of the IRE1α-mediated Unfolded Protein Response. Specifically, the study establishes a novel signaling axis where PDIA6 upregulates IRE1α, which in turn enhances the phosphorylation of HSP27 (predominantly at Ser78). This PDIA6–IRE1α–p-HSP27 axis is identified as a critical pathway for glioma progression.

The paper posits that PDIA6 serves a dual role:

1. Prognostic Biomarker: Its expression level correlates with tumor grade and patient survival, suggesting clinical utility in risk stratification.
2. Therapeutic Target: By elucidating the PDIA6–IRE1α–p-HSP27 mechanism, the study identifies this pathway as a potential target for therapeutic intervention in glioma.

The authors maintain a focused scope, stating that their findings "establish" this axis as a critical pathway and "identify" it as a target, without extrapolating to specific drug development or clinical trial designs beyond the scope of the reported mechanistic discovery.